Physician profile
Mohammad Mozayen
NPI 1437340668
$6,457.28
in general payments reported to CMS, 2019-2025
44 companies · $1,201 in 2025
The $1,201 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $45.42 · 2021: $208 · 2022: $914 · 2023: $2,627 · 2024: $1,358 · 2025: $1,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,166 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,165.99 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $1,333.32 | 2022-2025 | Cabometyx |
| Pfizer INC. | $511.64 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $434.58 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Novartis Pharmaceuticals Corporation | $372.63 | 2019-2025 | |
| Abbvie INC. | $329.53 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $325.60 | 2022-2025 | Calquence, Lynparza, Enhertu |
| Janssen Biotech, INC. | $248.75 | 2021-2025 | Erleada, Rybrevant, Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $242.05 | 2023-2025 | Opdivo, Opdualag, Krazati |
| Gilead Sciences, INC. | $222.19 | 2021-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $211.22 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Genentech USA, INC. | $200.93 | 2022-2025 | Polivy, Tecentriq, Lunsumio |
| Celgene Corporation | $191.66 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Eisai INC. | $184.82 | 2021-2025 | |
| Array Biopharma INC | $181.38 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Regeneron Healthcare Solutions, INC. | $176.38 | 2023-2025 | Libtayo |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $131.28 | 2022-2025 | Iclusig, Fruzaqla |
| Daiichi Sankyo INC. | $111.48 | 2023-2025 | Enhertu |
| Seagen INC. | $87.13 | 2021-2023 | Adcetris |
| Aveo Pharmaceuticals, INC. | $80.81 | 2022-2024 | |
| Kite Pharma, INC. | $79.32 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $74.43 | 2023-2025 | Onivyde, Tazverik, Somatuline Depot |
| Amgen INC. | $71.94 | 2019-2023 | Kyprolis, Blincyto |
| Karyopharm Therapeutics INC. | $63.99 | 2022-2023 | Xpovio |
| Pharmacyclics LLC, An Abbvie Company | $59.50 | 2023 | Epkinly, Imbruvica |
| Puma Biotechnology, INC. | $53.10 | 2022-2024 | |
| Incyte Corporation | $51.72 | 2021-2023 | Jakafi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.28 | 2021-2022 | |
| Novocure INC. | $44.78 | 2021-2025 | Optune Lua (Novottf-200t), Optune |
| Pharmaessentia USA Corporation | $43.28 | 2022-2023 | Besremi |
| Astellas Pharma US INC | $40.79 | 2023-2025 | Padcev, Vyloy |
| Genzyme Corporation | $40.29 | 2022-2024 | |
| Lilly USA, LLC | $37.13 | 2022-2024 | Verzenio, Jaypirca |
| Mirati Therapeutics, INC. | $24.43 | 2024 | Krazati |
| Foundation Medicine, INC. | $18.71 | 2023 | |
| Springworks Therapeutics, INC. | $18.05 | 2024 | Ogsiveo |
| G1 Therapeutics, INC. | $17.02 | 2023 | Cosela |
| Agios Pharmaceuticals, INC. | $16.31 | 2023 | Pyrukynd |
| Bayer Healthcare Pharmaceuticals INC. | $16.16 | 2025 | |
| Rigel Pharmaceuticals, INC. | $15.93 | 2023 | Tavalisse, Rezlidhia |
| Genmab U.S., INC. | $15.26 | 2024 | Tivdak |
| Stemline Therapeutics INC. | $15.20 | 2023 | Orserdu |
| Taiho Oncology, INC. | $11.28 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Mozayen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.